Abstract: Methods are provided for treating a cancer in a human patient in need thereof, comprising administering an effective amount of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] and a effective amount of etomoxir.

Abstract: A computer based method includes collecting biometric, physiological and other local data from one or more sensors or medical devices, including physiological data and/or conditions of a person. Remote data is collected including treatment information provided by a physician, and data obtained from various data transmitting sources such as RFID fitted pill dispensers, medication dispensers, intra body devices, medical data sensors and medical apparatus. All the data is preferably obtained in real time and stored in an encrypted database which is either maintained in a local data storage device or in a remotely located secure database. Control and access to any or parts of the data collected is controlled by the person, preferably secured using biometric information, so each individual person can maintain control over the collected information, and prevent inadvertent disclosures to persons without a need to know.

Abstract: A therapeutic method for treating hepatocellular carcinoma is disclosed comprising administering to a patient in need of treatment a ruthenium complex salt.

Abstract: Methods and compositions for treating brain cancer are disclosed, including refractory brain cancer.

Abstract: Methods and compositions for treating hematological cancer are disclosed, including refractory or resistant hematological cancer.

Abstract: Methods and compositions for treating brain cancer are disclose including refractory brain cancer.

Abstract: A therapeutic method for treating hepatocellular carcinoma is disclosed comprising administering to a patient in need of treatment a ruthenium complex salt.

Abstract: The invention relates to the use of gallium (III) complexes for the treatment of melanomas.

Abstract: The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M3-n-p-2pr[RuX6-n-p-q-2rBn(H2O)p(OH)q(O)r]2r+1??(I) with a compound of the general formula (II) B?(HX?)S??(II).

Abstract: The invention relates to the use of gallium (III) complexes for the treatment of melanomas.

Abstract: Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M3?n?p?2pr[RUX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(I) with a compound of the general formula (II) B?(HX?)s??(II). Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III) (B?H)3?n?p?2pr[RUX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(III) with a compound of the general formula (IV) MX???(IV).

Abstract: Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M3?n?p?2pr[RuX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(I) with a compound of the general formula (II) B?(HX?)S.??(II) Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III) (B?H)3?n?p?2pr[RuX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(III) with a compound of the general formula (IV) MX?.

Abstract: There is disclosed a method comprising the steps of: 1. sensing biometric characteristic data of an individual; 2. comparing said biometric characteristic data to characteristic data of predetermined registered individuals and determining whether said individual is registered; 3. sensing physiological characteristic data of said individual; 4. comparing said physiological characteristic data with a predetermined range of acceptable values for said physiological characteristic data; and 5. sensing a parameter characteristic of a security condition; 6. comparing said parameter characteristic of a security condition with a predetermined range of acceptable values for said parameter 7. transmitting a signal if said individual is registered, if said physiological characteristic data is within said predetermined range or not and if said parameter characteristic of a security condition is within said range of acceptable values for said parameter.

Abstract: Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M3-n-p-2pr[RuX6-n-p-q-2rBn(H2O)p(OH)q(O)r]2r+1 ??(I) with a compound of the general formula (II) B?(HX?)S ??(II). Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III) (B?H)3-n-p-2pr[RuX6-n-p-q-2rBn(H2O)p(OH)q(O)r]2r+1 ??(III) with a compound of the general formula (IV) MX???(IV).

Abstract: Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M3?n?p?2pr[RUX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(I) with a compound of the general formula (II) B?(HX?)s??(II). Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III) (B?H)3?n?p?2pr[RUX6?n?p?q?2rBn(H2O)p(OH)q(O)r]2r+1??(III) with a compound of the general formula (IV) MX???(IV).

Abstract: A conjugate includes at least one target-seeking unit, which specifically binds to receptors on the surface of endothelial cells, and at least one effector unit which is coupled to the unit by a linker. The effector unit exhibits at least one signal unit and optionally at least one therapeutic active substance. The target-seeking unit includes a lectin or a fragment or derivative thereof, wherein the lectin is not L-selectin and the signal unit includes a lanthanide ion.

Abstract: Lanthanum compounds are provided having general formulas (I) Rni+Yin? and (II) Rb+Yb? which may be used as medicaments in the prophylaxis and/or treatment of cancer diseases.

Abstract: A tumor-inhibiting platinum (II) oxalate complex and its use as a therapeutic agent are provided, in particular as a tumor-inhibiting medicament.

Abstract: The invention relates to a compound of the general formula (I) where R1, R2, R3, R4, R1?, R2?, R3? and R4? are independently of one another hydrogen, C1–C15-alkyl, C2–C15-alkenyl, C2–C15-alkinyl, C3–C16-cycloalkyl, C3–C16-cycloalkenyl, aryl or a heterocyclus which in each case can be substituted or unsubstituted, Y is a physiologically compatible anion, and n is 1 or 2, as well as its application to the prophylaxis and/or tretment of cancer illnesses.

Abstract: This invention relates to anellated azepinone derivatives, a method of their production, metal complexes of the anellated azepinone derivatives as well as their use in the treatment of tumor diseases.